Lat­est news on pa­tient death in n-of-1 CRISPR tri­al; Good news for RSV; Vac­cine R&D rev­o­lu­tion; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

This is the rare week where End­points News is mak­ing news. If you haven’t heard, Drew Arm­strong will be join­ing us from Bloomberg to be­come our new ex­ec­u­tive ed­i­tor. We are thrilled to have him on board. Read founder and ed­i­tor John Car­roll’s note about our big an­nounce­ment — and what that means for End­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER